Shape Pharmaceuticals
  • Contact
  • Sitemap
  • About
  • CTCL Therapeutic Program
  • Publications & Presentations
  • News & Events

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical HDAC inhibitor, currently in early clinical development, for the treatment of patients with cutaneous T cell lymphoma (CTCL). The development of SHP-141 is being supported through a Therapeutic Accelerator Program partnership with the Leukemia & Lymphoma Society, which is providing funding of up to $3.3 million. Shape is a Healthcare Ventures funded focused company founded by James E. Bradner, M.D., and Ralph Mazitschek, Ph.D.

Shape Pharmaceuticals, Inc. has been acquired by TetraLogic Pharmaceuticals effective April 14, 2014.

Please visit TetraLogic Pharmaceuticals for more information.


TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc.


Shape Pharmaceuticals Provides Update on SHP-141 Topical HDAC Inhibitor Clinical Development for Cutaneous T Cell Lymphoma